Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family Chair, Melanoma Research and Treatment Moffitt Cancer Center Disclosures • Celgene Corp. (Business Strategy Advisory Board) • Etubics Corp. (SAB) • Kite Pharma, Inc. (Consultant) • Lion Biotechnologies (SAB) • Lycera Corporation (SAB) • OncoPep, Inc. (SAB) • Oxis Biotechnologies, Inc. (SAB) • Select Bioventures (Advisory Board) • Vault Nano, Inc. (SAB) Immunotherapy for Solid Tumors: Basic Requirements for Successful Clinical Response 1. Immune T cell infiltration into the tumor mass: More is better 2. Gene mutation load: More is better (creation of foreign neoantigens) Immunotherapy for Solid Tumors: Basic Requirements for Successful Clinical Response Immune T cell infiltration into the tumor mass: More is better Adoptive T Cell Transfer • Tumor Infiltrating Lymphocytes (TIL) Tumor-Infiltrating Lymphocytes (TIL) for Treatment of Metastatic Melanoma    